Vijaya Diagnostics Q3 Results Review - Rangebound Margin Despite Healthy Growth: Yes Securities

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Yes Securities Report.Vijaya Diagnostics Center Ltd. reported in line revenues while margin was slightly ahead; company merged PH Diagnostic after the acquisition was completed in late December 2023. Management expects to stick to its 15 centre addition target in FY25 which would likely keep margin in a range of 41-42% over next two years.So far, the hubs added in FY23 and FY24 have been on track for break even time line as outlined earlier which implies healthy footfall ramp up at these new hub locations.We trim FY24 estimate on back of lower than expected patient footfall (though tests volume is in mid-teens) so far and also factor in one-off acquisition related cost. Incorporate full year sales of PH Diagnostic in FY25 though trimmed base of FY24 means there is no change to FY25 estimates.Roll over to FY26 estimates with unchanged 35 times target earning price and revised target price Rs 610 (earlier Rs 560)..Click on the attachment to read the full report:.Prince Pipes Q3 Results Review - Measures Taken To Re-Gain Lost Market Share From Q1 FY25: Systematix.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Vijaya Diagnostics Q3 Results Review - Rangebound Margin Despite Healthy Growth: Yes Securities

Margin just ahead of estimate but below 40% as negative operating leverage offset healthy topline growth.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Vijaya Diagnostics Q3 Results Review - Rangebound Margin Despite Healthy Growth: Yes Securities

Margin just ahead of estimate but below 40% as negative operating leverage offset healthy topline growth.

Choose a plan

Follow Us

DOWNLOAD THE APP